Oxford Biomedica rejects EQT takeover approach
#Oxford Biomedica #EQT takeover #LSE:OXB #City Code on Takeovers #Viral vectors #Biotech acquisitions #Pharmaceutical M&A #Shareholder value
📌 Key Takeaways
- Oxford Biomedica rejected all four takeover proposals from EQT
- EQT has withdrawn from making an offer and is now bound by takeover restrictions
- The board determined that EQT's offers undervalued the company
- Oxford Biomedica specializes in viral vector development and manufacturing
📖 Full Retelling
Oxford Biomedica plc (LSE:OXB) announced Tuesday that EQT has withdrawn from making an offer for the company after the board rejected four acquisition proposals, including possible cash offers and an unlisted share alternative, with the board concluding after consulting key shareholders that the proposals undervalued the company. The London-based biotech firm revealed that EQT submitted multiple proposals throughout the takeover process, with two additional offers coming after the initial possible announcement on January 14, 2026. Following the board's unanimous rejection, EQT confirmed it does not intend to proceed with an acquisition, effectively ending the takeover attempt that had been developing for over a month. The company had previously extended its Put Up or Shut Up (PUSU) deadline on February 11, indicating ongoing discussions between the parties. With the withdrawal, EQT is now bound by the restrictions outlined in Rule 2.8 of the City Code on Takeovers and Mergers, preventing it from making another approach for a specified period without board approval. Oxford Biomedica operates as a contract development and manufacturing organization specializing in viral vectors including lentivirus, adeno-associated virus, and adenovirus, positioning it as a key player in the gene therapy and vaccine development sectors.
🏷️ Themes
Corporate Takeovers, Pharmaceutical/Biotech Industry, Market Valuation
📚 Related People & Topics
Viral vector
Biotechnology for gene delivery
A viral vector is a modified virus designed to deliver genetic material into cells. This process can be performed inside an organism or in cell culture. Viral vectors have widespread applications in basic research, agriculture, and medicine.
Oxford Biomedica
BioTech Company
Oxford Biomedica (OXB) is a gene and cell therapy company specialising in the development of gene-based medicines. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Nvidia, Salesforce earnings loom large - what’s moving markets Gold prices rebound on tariff jitters; silver, platinum and copper rally Nvidia set to report strong results and guidance, analysts say U.S. stock futures drift higher; Nvidia earnings to drive direction (South Africa Philippines Nigeria) Oxford Biomedica rejects EQT takeover approach By Investing.com Company News Published 02/25/2026, 07:34 AM Oxford Biomedica rejects EQT takeover approach 0 OXB -4.90% LONDON - Oxford Biomedica plc (LSE:OXB) announced Tuesday that EQT has withdrawn from making an offer for the company after the board rejected four acquisition proposals. EQT submitted four proposals to Oxford Biomedica’s board, including two after the initial possible offer announcement on January 14, which included possible cash offers and an unlisted share alternative. The board, after consulting with key shareholders, unanimously concluded that the proposals undervalued the company and rejected them. Following the withdrawal, EQT is bound by the restrictions set out in Rule 2.8 of the City Code on Takeovers and Mergers, according to a press release statement from Oxford Biomedica. The company had announced on February 11 that the PUSU deadline was being extended. EQT confirmed earlier Tuesday that it does not intend to make an offer for Oxford Biomedica. Oxford Biomedica operates as a contract development and manufacturing organization specializing in viral vectors including lentivirus, adeno-associated virus, and adenovirus. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read full article at source